FOLH1 and neoplasm: Therefore, the nanoplatforms containing ligands targeting FAP and PSMA, such as 177Lu2O3-iFAP, 177Lu2O3-iPSMA, or even hybrid 177Lu2O3-iFAP/iPSMA systems could improve tumor retention due to their specific binding to both fibroblasts and tumor neovasculature (Figure 7).